Table 2.
Base-case analysis by PPMA uptake rate
| Prescribing strategy (uptake rate) | PDS: Cost ($CAD)1,2 | PDS: ΔCost ($CAD)1,2 | PAS: Cost ($CAD)1,2 | PAS: ΔCost ($CAD)1,2 | ΔED visits3 | ΔFMD visits3 | ΔWalk-in clinic visits3 |
|---|---|---|---|---|---|---|---|
| (A) Upper respiratory tract infections | |||||||
| UCM | 52.21 | n/a | 52.40 | n/a | n/a | n/a | n/a |
| PPMA (0%) | 52.21 | 0 | 52.40 | 0 | –20 | –85 | +11 |
| PPMA (20%) | 48.26 | –3.95 | 45.85 | –6.36 | –194 | –815 | –1021 |
| PPMA (38%) | 44.70 | –7.51 | 39.95 | –12.26 | –366 | –1463 | –1968 |
| PPMA (60%) | 40.35 | –11.86 | 32.74 | –19.47 | –593 | –2238 | –3101 |
| PPMA (80%) | 36.40 | –15.81 | 26.18 | –26.03 | –799 | –2923 | –4132 |
| PPMA (100%) | 32.45 | –19.76 | 19.63 | –32.58 | –1000 | –3589 | –5147 |
| (B) Contact dermatitis | |||||||
| UCM | 54.45 | n/a | 54.45 | n/a | n/a | n/a | n/a |
| PPMA (0%) | 54.45 | 0 | 54.45 | 0 | +3 | –16 | –39 |
| PPMA (20%) | 52.31 | –2.15 | 51.87 | –2.58 | –65 | –581 | –930 |
| PPMA (38%) | 50.37 | –4.08 | 49.56 | –4.89 | –127 | –1111 | –1663 |
| PPMA (60%) | 48.02 | –6.43 | 46.72 | –7.73 | –196 | –1738 | –2630 |
| PPMA (80%) | 45.87 | –8.58 | 44.14 | –10.31 | –285 | –2302 | –3468 |
| PPMA (100%) | 43.72 | –10.73 | 41.57 | –12.88 | –342 | –2868 | –4361 |
| (C) Conjunctivitis | |||||||
| UCM | 69.23 | n/a | 69.40 | n/a | n/a | n/a | n/a |
| PPMA (0%) | 69.23 | 0 | 69.40 | 0 | –3 | –29 | –12 |
| PPMA (20%) | 66.52 | –2.17 | 64.52 | –4.88 | –159 | –596 | –735 |
| PPMA (38%) | 64.08 | –5.15 | 60.13 | –9.27 | –306 | –1103 | –1459 |
| PPMA (60%) | 61.09 | –8.14 | 54.77 | –14.63 | –563 | –1688 | –2240 |
| PPMA (80%) | 58.38 | –10.85 | 49.90 | –19.50 | –736 | –2174 | –2957 |
| PPMA (100%) | 55.67 | –13.56 | 45.03 | –24.37 | –935 | –2653 | –3688 |
Abbreviations: UCM, usual care model; RM, RPh model; PDS, prescription-detached scenario; PAS, prescription-attached scenario; ED, emergency department; FMD, family physician; n/a, not applicable; PSA, probabilistic sensitivity analysis; $CAD, Canadian dollars.
All costs are shown in 2019 Canadian dollars. 1Per patient; 2Based on PSA of 10 000 replications; 3Per 10 000 patients.